UBS Initiates Coverage On Wave Life Sciences with Buy Rating, Announces Price Target of $11

UBS analyst Joon Lee has initiated coverage on Wave Life Sciences (NASDAQ: WVE) with a Buy rating. The firm has set a price target of $11 for the company's stock.